On January 10, 2024 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, reported that it will present an overview of its business and clinical programs at the Sidoti Micro-Cap Virtual Conference, taking place January 17-18, 2024 (Press release, Anixa Biosciences, JAN 10, 2024, View Source [SID1234639177]). Anixa Chairman and CEO Dr. Amit Kumar will present on Wednesday, January 17, 2024, at 12:15 PM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are as follows:

Presentation:

Wednesday, January 17, 2024, at 12:15 PM ET

Presentation link:

Click here to register; available live and on demand

Conference registration:

Available on the conference website

1×1 meetings:

Open to all investors upon conference registration

During his presentation, Dr. Kumar will provide an overview of Anixa’s clinical programs including vaccines to prevent cancer and a CAR-T cell therapy to treat cancer. He will also review recently announced positive results from the Phase 1 clinical trial of Anixa’s breast cancer vaccine. The vaccine is designed to direct the immune system to destroy triple negative breast cancer (TNBC) cancer cells through a mechanism that has never previously been utilized for cancer vaccine development.